Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery

J Med Chem. 2014 Sep 25;57(18):7613-23. doi: 10.1021/jm500759v. Epub 2014 Sep 8.

Abstract

Human parainfluenza virus type 1 is the major cause of croup in infants and young children. There is currently neither vaccine nor clinically effective treatment for parainfluenza virus infection. Hemagglutinin-neuraminidase glycoprotein is a key protein in viral infection, and its inhibition has been a target for 2-deoxy-2,3-didehydro-d-N-acetylneuraminic acid (Neu5Ac2en)-based inhibitor development. In this study, we explore the effect of C-5 modifications on the potency of Neu5Ac2en derivatives that target the human parainfluenza type-1 hemagglutinin-neuraminidase protein. Our study demonstrates that the replacement of the Neu5Ac2en C-5 acetamido moiety with more hydrophobic alkane-based moieties improves the inhibitory potency for both hemagglutinin-neuraminidase functions. These findings shed light on the importance of C-5 substitution on Neu5Ac2en in the design of novel sialic acid-based inhibitors that target human parainfluenza type-1 hemagglutinin-neuraminidase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / chemistry
  • Amides / pharmacology*
  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Drug Evaluation, Preclinical
  • HN Protein / chemistry
  • HN Protein / metabolism*
  • Inhibitory Concentration 50
  • Molecular Dynamics Simulation
  • Parainfluenza Virus 1, Human / drug effects*
  • Protein Conformation

Substances

  • Amides
  • Antiviral Agents
  • HN Protein